Literature DB >> 6200498

Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line.

D B Wilson, H H Salem, J S Mruk, I Maruyama, P W Majerus.   

Abstract

A human hepatocellular carcinoma line, HepG2, was found to secrete coagulation Factor V. Factor V activity in HepG2 culture fluid increased nearly linearly during a 20-h time course (5 ng Factor Va/h per 10(6) cells). Thrombin treatment increased Factor V activity in HepG2 culture medium six- to ninefold, indicating that the medium accumulates a mixture of Factors V and Va. To demonstrate de novo synthesis of Factor V, HepG2 cells were incubated in culture medium containing [35S]methionine. Labeled Factor V was immunoprecipitated from the medium and was shown to co-migrate with purified plasma Factor V upon sodium dodecyl sulfate polyacrylamide gel electrophoresis and fluorography. When medium was treated with thrombin before immunoprecipitation and fluorography, the 330,000-Mr [35S]methionine-labeled Factor V was converted to Factor Va. Factor Va coagulant activities from HepG2 cells and human plasma were inhibited in parallel by anti-Factor V antibody, indicating that HepG2 and plasma Factor Va have the same intrinsic activity. If normal hepatocytes synthesize Factor V at the same rate as HepG2 cells, then hepatocyte secretion can account for the total Factor V present in plasma. The production of Factor V by cultured human umbilical vein endothelial cells was also examined. Spent culture medium from endothelial cells contained only Factor Va and the amount was less than 1% of the activity found in medium from HepG2 cells under comparable conditions. The amount of Factor V activity in endothelial cell culture fluid did not change with time in culture.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6200498      PMCID: PMC425065          DOI: 10.1172/JCI111256

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  The immunological localization of factor V in human tissue.

Authors:  J C Giddings; S A Shearn; A L Bloom
Journal:  Br J Haematol       Date:  1975-01       Impact factor: 6.998

2.  Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins.

Authors:  H Hjelm; K Hjelm; J Sjöquist
Journal:  FEBS Lett       Date:  1972-11-15       Impact factor: 4.124

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Disappearance rates of coagulation factors: transfusion studies in factor-deficient patients.

Authors:  E J Bowie; J H Thompson; P Didisheim; C A Owen
Journal:  Transfusion       Date:  1967 May-Jun       Impact factor: 3.157

5.  Synthesis of clotting factors by the isolated perfused rat liver.

Authors:  J P Olson; L L Miller; S B Troup
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

6.  Coagulation abnormalities in liver disease.

Authors:  K Lechner; H Niessner; E Thaler
Journal:  Semin Thromb Hemost       Date:  1977       Impact factor: 4.180

7.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

8.  Hemorrhagic death associated with a high titer factor V inhibitor.

Authors:  M C Coots; A F Muhleman; H I Glueck
Journal:  Am J Hematol       Date:  1978       Impact factor: 10.047

9.  Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.

Authors:  J P Miletich; D W Majerus; P W Majerus
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  13 in total

1.  Hepatocarcinoma in cirrhosis. Is antithrombin III a neoplastic marker?

Authors:  A Grieco; V De Stefano; A Cassano; A Ciabattoni; C Garufi; A Astone; G Leone; C Barone
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.

Authors:  W H Kane; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

3.  Induction of haem synthesis in Hep G2 human hepatoma cells by dimethyl sulphoxide. A transcriptionally activated event.

Authors:  R A Galbraith; S Sassa; A Kappas
Journal:  Biochem J       Date:  1986-07-15       Impact factor: 3.857

4.  Identifying and enriching platelet-producing human stem cell-derived megakaryocytes using factor V uptake.

Authors:  Xiuli Sim; Danuta Jarocha; Vincent Hayes; Hayley A Hanby; Michael S Marks; Rodney M Camire; Deborah L French; Mortimer Poncz; Paul Gadue
Journal:  Blood       Date:  2017-04-28       Impact factor: 22.113

5.  Development and Characterization of a Factor V-Deficient CRISPR Cell Model for the Correction of Mutations.

Authors:  Luis Javier Serrano; Mariano Garcia-Arranz; Juan A De Pablo-Moreno; José Carlos Segovia; Rocío Olivera-Salazar; Damián Garcia-Olmo; Antonio Liras
Journal:  Int J Mol Sci       Date:  2022-05-22       Impact factor: 6.208

6.  Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Authors:  T L Ortel; M A Quinn-Allen; L A Charles; D Devore-Carter; W H Kane
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

7.  Coagulation factor Va binds to human umbilical vein endothelial cells and accelerates protein C activation.

Authors:  I Maruyama; H H Salem; P W Majerus
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency.

Authors:  Keiko Shinozawa; Kagehiro Amano; Takashi Suzuki; Asashi Tanaka; Kenji Iijima; Hoyu Takahashi; Hiroshi Inaba; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

9.  A case of coagulation factor V deficiency complicated with intracranial hemorrhage.

Authors:  S G Yoon; S T Cho; S K Park; J H Won; S H Baick; D S Hong; H S Park
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

10.  Generation of coagulation factor V activity by cultured rabbit alveolar macrophages.

Authors:  H Rothberger; M P McGee
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.